Menlo Therapeutics (MNLO) Coverage Initiated at Jefferies Group

Analysts at Jefferies Group assumed coverage on shares of Menlo Therapeutics (NASDAQ:MNLO) in a research report issued to clients and investors on Tuesday, February 20th, reports. The brokerage set a “buy” rating and a $41.00 price target on the stock. Jefferies Group’s price target would suggest a potential upside of 30.49% from the stock’s previous close. Jefferies Group also issued estimates for Menlo Therapeutics’ Q1 2018 earnings at ($0.78) EPS, Q2 2018 earnings at ($0.76) EPS, Q3 2018 earnings at ($0.80) EPS, Q4 2018 earnings at ($0.74) EPS, FY2018 earnings at ($3.08) EPS, FY2019 earnings at ($4.06) EPS, FY2020 earnings at ($3.39) EPS, FY2021 earnings at ($2.34) EPS and FY2022 earnings at ($3.86) EPS.

Separately, Guggenheim started coverage on Menlo Therapeutics in a report on Monday, February 19th. They set a “buy” rating and a $52.00 price target for the company.

Menlo Therapeutics (MNLO) traded down $1.98 during trading on Tuesday, reaching $31.42. 147,519 shares of the company’s stock were exchanged, compared to its average volume of 151,973. Menlo Therapeutics has a 52 week low of $20.50 and a 52 week high of $39.86.

In other news, major shareholder Vivo Capital Surplus Fund Viii purchased 294,118 shares of the business’s stock in a transaction dated Thursday, January 25th. The shares were purchased at an average cost of $17.00 per share, with a total value of $5,000,006.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

TRADEMARK VIOLATION NOTICE: This article was originally posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this article on another domain, it was stolen and republished in violation of United States and international copyright and trademark law. The original version of this article can be read at

Menlo Therapeutics Company Profile

Menlo Therapeutics Inc is a United States-based biopharmaceutical company. The Company is focused on the development and commercialization of serlopitant for the treatment of pruritus (itch) associated with dermatologic conditions, such as atopic dermatitis, psoriasis and prurigo nodularis. It is also evaluating the use of serlopitant for the treatment of refractory chronic cough.

Receive News & Ratings for Menlo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Menlo Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply